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Introduction
Mycotoxins are naturally occurring secondary chemical metabolites produced by different fungi genera such as Aspergillus, Fusarium, Penicillium, Alternaria and Claviceps [1] . Among these genera, Fusarium fungi are the most widespread in cereal crop production. Fusarium fungi produce a diversity of mycotoxin types and can have widespread geographical distribution influenced primarily by environmental and climatic conditions and crop production, storage, processing and transportation methods. Toxins produced by Fusarium moulds, include fumonisins, trichothecenes (deoxynivalenol, T2 and HT2 toxin) and zearalenone. Mycotoxins are chemically and thermally stable whereby mycotoxin contamination of raw materials may also affect processed foods [2] . Furthermore they can enter the food chain through animals fed contaminated feed [3] . Mycotoxin contamination is inhomogeneous in nature and the toxins can be present at very low levels. Due to their highly resistant nature they can remain in the food chain [4] thereby posing a threat as toxic contaminants of food products.
The complex toxic effects of mycotoxins pose significant health risks to humans and animals and this necessitates for effective control and surveillance procedures [5] [6] [7] [8] [9] . The initial stages in the protection against mycotoxin contamination is through the adoption of good agricultural, storage and processing practices to ensure mycotoxin levels remain negligible or as low as reasonably achievable [10] . In order to protect consumer safety, legislative limits for mycotoxins in certain foodstuffs are set out by the European Commission [11] [12] [13] [14] .
Contamination of food by these natural toxins is of an increasing safety and economic concern due to changes in prevalence with variations in environmental conditions. Therefore, innovation in the development of detection methods for implementation is vitally important.
The detection of mycotoxins is carried out by confirmatory methods for quantitative analysis and by rapid diagnostics for screening. Several validated methods are available for the measurement of mycotoxins and the literature on this subject has included many comprehensive and critical reviews [8, [15] [16] [17] [18] [19] . For the quantitative analysis of mycotoxins high performance liquid chromatography (HPLC), gas chromatography (GC) and thin layer chromatography (TLC) as well as multiple toxin mass spectrometry (MS) methods are used [20] [21] [22] [23] [24] . These methods, however, require the use of complex and expensive equipment as well as skilled operators and extensive sample pre-treatment. Furthermore, these methods sometimes may not reach the very low limit of detection required. Immunoassays are often employed for the screening of mycotoxin contamination as they provide rapid, sensitive detection and easy to use methods. Immunological methods such as enzyme linked immunosorbent assay (ELISA) [25] [26] [27] [28] [29] and lateral flow devices (LFD) [30] [31] [32] [33] are the most common approaches. These detection methods are simpler in design, inexpensive, fast, robust, user friendly and cost effective allowing high sample throughput with high sensitivity and accuracy. LFDs provide a 'yes/no' answer, however, in recent years modified devices enabling quantitative evaluation and multiplexing have been developed. In the Conffidence project funded by the European Union, a LFD enabling the simultaneous detection of Fusarium toxins (deoxynivalenol, zearalenone, T2/HT2 toxins, fumonisins) in cereals was developed [34] and now commercialised by Unisensor (Belgium). Commercial detection tests based on both ELISA and LFDs are also available for many of the mycotoxins from Tecna (Italy), R-Biopharm (Germany), Europroxima (The Netherlands), Neogen (USA), Charm Sciences (USA), Diachemix (USA), Envirologix (USA), Romer Labs (USA) and Vicam (USA) but are all based on single toxin analysis for these mycotoxins. Randox (Crumlin, UK) offer a commercial test for multiple mycotoxin detection based on a customised biochip with chemiluminescent detection using relatively expensive closed technology.
In addition to safety issues, natural toxin contamination of food is of great economic concern; much effort is therefore devoted to the development of novel, rapid, inexpensive, simple and sensitive multiple mycotoxin screening methods. The simultaneous identification of several mycotoxins in one single test, reducing time and costs per analysis is a most attractive option.
Nanoarrays are important tools for high throughput analysis enabling miniaturization, higher sensitivity and simplified sample preparation and offer a number of applications in the areas of medical diagnosis, genetic testing, environmental monitoring and food safety. In recent years the nanoarray format has provided a powerful tool in which several targets are separately detected in spatially defined zones simultaneously. Oswald et al. (2013) described a multiple mycotoxin immunoassay using the Munich chip reader 3 platform and reusable biochips. A number of mycotoxins including aflatoxin, ochratoxin A, FUM and DON were spotted onto glass slides and detected in cereals using chemiluminescence [35] . Additionally, Beizaei et al.
(2015) reported a rapid and highly sensitive microarray method for aflatoxin B1 detection in cereals using 16-pad nitrocellulose coated FAST slides [36] . The application of nanotechnology faces many challenges in order to produce successful commercial products that can compete with the traditional methods of mycotoxin analysis. In this study, it is intended to introduce the concept and advantages of nanotechnology to the food industry and describe the proof of concept and feasibility of a nanoarray for the simultaneous detection of three harmful mycotoxins. There are very few studies that effectively employ this promising technology for the detection of mycotoxins. Innovative nano science and technology with state of the art sensing equipment have allowed novel detection methods to become a reality. The aim of this research was therefore to develop a multiplex nanoarray for the simultaneous detection of three regulated Fusarium mycotoxins offering high throughput in the 96 well plate format compared to LFD platforms.
Materials and methods

Instrumentation
A sciFLEXARRAYER S5 (Scienion, Germany) was used for spotting microtitre plates and a sciReader CL colorimetric nanoarray reader (Scienion, Germany) was used for scanning and analysing spot intensities.
Reagents
Antibodies for ZEA, T2 and FUM and mycotoxin-BSA conjugates for ZEA (3.39 mg/ml), T2
(1.5 mg/ml) and FUM (1.32 mg/ml) were provided by Tecna (Tecna s.r.l, Trieste, Italy). Nunc 96 well microtitre plates were purchased from VWR (Leicestershire, UK). Alkaline phosphatase substrate was purchased from Millipore (Hertfordshire, UK). Bovine serum albumin (BSA), anti-rabbit IgG-alkaline phosphatase antibody produced in goat, 5-bromo-4chloro-3'-indolyphosphate (BCIP), nitro-blue tetrazolium (NBT), methanol (HPLC grade), zearalenone, deoxynivalenol and HT2-toxin were all purchased from Sigma-Aldrich (Dorset, UK). Fumonisin B1 was purchased from Trilogy (Darmstadt, Germany). T2-toxin, fumonisin B2 and fumonisin B3 were purchased from Romer Labs (Cheshire, UK).
Printing nanoarrays
BSA-conjugated mycotoxins were diluted in filtered printing buffer (100 mM sodium phosphate, 50 mM sodium chloride, 100 μg/ml BSA, 0.005 % Tween-20, pH 8.0) at 50 µg/ml.
A spotting volume of 1000 pl for each reagent was spotted onto a 96 well microtitre plate using a sciFLEXARRAYER S5. For part one of the study (single spotting analysis) a nine spot matrix format (3x3 array) was arrayed with a 1000 µm spot to spot pitch composing of nine replicates of each target in separate wells. For part two of the study (multi spotting analysis) a 12 spot matrix format (4x3 array) was arrayed with a 750 µm spot to spot pitch composing of four replicates of each target (x 3 targets) in the same well. All spotting was carried out at room temperature and 65 % humidity. Microtitre plates were left at 65 % humidity for 1 hr on the nanospotter before being stored at 25 °C and 30 % humidity overnight in a humidity chamber (Deny, China).
Assay protocol
The microtitre plate was blocked with 0.2 % BSA (100 µl) for 60 min at room temperature followed by 3 washes with ELISA wash solution (0.15 M NaCl, 0.0125 % Tween) and dried on lint free paper. Antibody (50 µl) diluted in PBS (0.1 M, pH 7.2) and sample/standard (50 µl) diluted in PBS (0.1 M, pH 7.2) were applied to each well and incubated for 40 min at room temperature. The microtitre plate was washed 3 times with ELISA wash solution and dried with lint free paper. Alkaline phosphatase anti-rabbit IgG (100 µl) diluted 1/500 in PBS (0.1 M, pH 7.2) was added to each well and incubated for 20 min at room temperature. The microtitre plate was washed 3 times with ELISA wash solution and dried with lint free paper. BCIP/NBT substrate (100 µl) was added to each well and incubated for 10 min at room temperature. Finally, the microtitre plate was washed 3 times with ELISA wash solution and dried with lint free paper.
Image and data processing
Microtitre plates were scanned using the sciReader colorimetric nanoarray reader at an exposure of 100 ms. An image of each well of the microtitre plate was taken and saved as a TIFF file. One microtitre plates takes approximately 1 min to scan. The images are opened and processed using sciANA software from Scienion. The spotting matrix of each well is defined by the number of blocks (1x1) and number of spots (4x3) so that the software knows the spotting configuration. Next the image is evaluated and the software attempts to find the spotting configuration that has been specified. If the software successfully detects the spots it will draw grids around each spot automatically. If the intensity between the spots and the background is similar the software will not be able to find the spots and instead the grids must be manually aligned by the user. Once grids are aligned the data can be exported into excel.
The excel sheet will contain information on each spot of the well including for example X and Y coordinates, diameter, median intensity of spot and intensity of background. The median intensity (with background removed) measured in pixels is used for further data analysis.
Optimisation
A chequerboard design was employed to optimise the assay parameters. Microtitre plates were spotted in a single system (ZEA, T2 or FUM) to determine optimum parameters for each mycotoxin. Single antibodies to each mycotoxin were assessed. For ZEA microtitre plates were spotted at varying spotting volumes (330, 670, 1000, 2000 pl) at varying protein concentrations (0.5, 5 and 50 µg/ml) of the ZEA-BSA conjugate. For T2 and FUM a spotting volume of 1000 pl at varying protein concentrations of 10, 50, 100 and 200 µg/ml of the mycotoxin-BSA conjugates were assessed. Two antibodies were compared for T2 (ABT-1 and ABT-2) and FUM (ABF-1 and ABF-2) while only one antibody was available for ZEA (ABZ). These were assessed at different dilutions ranging from 1/500 -1/15,000. A negative and positive standard were assessed for each parameter to determine optimum spotting conditions for each mycotoxin.
Individual calibration curves
Microtitre plates were spotted in a single system (ZEA, T2 or FUM) to assess individual calibration curves for each mycotoxin. Spotting parameters and the assay parameters were determined during the optimisation stage. The microtitre plates were spotted using mycotoxin-BSA conjugates at a spotting volume of 1000 pl and a protein concentration of 50 µg/ml for all three mycotoxin-BSA conjugates. Single antibodies for ZEA ABZ (1/10,000), T2-ABT-1 
Multiplex calibration curves
Microtitre plates were spotted in a three-plex system (ZEA, T2 and FUM) to assess multiplex calibration curves for each mycotoxin. Spotting and assay parameters were determined during the optimisation stage. Microtitre plates were spotted using mycotoxin-BSA conjugates at a spotting volume of 1000 pl and a protein concentration of 50 µg/ml for all three mycotoxin-BSA conjugates. Antibodies for ZEA (ABZ 1/10,000), T2 (ABT-1 1/4000) and FUM (ABF-2 1/4000) were examined during the assay. Eight point calibration curves for ZEA, T2 and FUM were prepared in PBS and methanol at concentrations across the full dynamic range for a full evaluation for individual mycotoxin analysis. Where necessary additional standards were added to improve the curve shape. Multiplex calibration curves were assessed and examined (n=6 analysis, 4 spots per analysis, 3 spotting days) and sensitivity was assessed using the 50 % inhibition concentration. The 50 % inhibition concentrations were determined from a 4 parameter fit curve using BIAevaluation version 4.1 software (Biacore, GE Healthcare).
Cross reactivity
Microtitre plates were spotted as described in section 3.7. Antibodies for ZEA (ABZ 1/10,000), T2 (ABT-1 1/4000) and FUM (ABF-2 1/4000) were examined during the assay for ZEA, T2, HT2, FUM B1, FUM B2, FUM B3, DON as individual calibration curves. Eight point calibration curves were prepared in methanol at concentrations across the full dynamic range for an evaluation of each mycotoxin. Where necessary additional standards were added to improve the curve shape so that the IC50 of the curve could be determined. Cross reactivity was determined from the following calculation whereby the main mycotoxin refers to ZEA, T2 and FUM B1. % Cross reactivity = IC50 main mycotoxin / IC50 mycotoxin to be determined x 100
Intra and inter spotting precision
Microtitre plates were spotted as described in section 3.7. Antibodies for ZEA (ABZ 1/10,000), T2 (ABT-1 1/4000) and FUM (ABF-2 1/4000) were examined during the assay. Intra-spotting precision (n=96) was examined by analysing the mean intensity, of the maximum antibody binding achieved, on application of the 0 ppb standard in all 96 wells of the microtitre plate prepared using both PBS and methanol. Inter-spotting precision was assessed and examined over three separate spotting days. The mean intensity, of the maximum antibody binding achieved on application of the 0 ppb standard, from all 96 wells was calculated and compared over the three different spotting days. Intra and inter spotting precision was determined from the coefficient of variation (% CV). 
Intra
Matrix effects
Microtitre plates were spotted as described in section 3.7. Antibodies for ZEA (ABZ 1/10,000), T2 (ABT-1 1/4000) and FUM (ABF-2 1/4000) were examined during the assay. Blank material for both maize and wheat were sourced by Queen's University Belfast and were confirmed as blank for the analytes of interest by mass spectrometry. Six calibration curves were examined including PBS, methanol, maize spiked at the start of extraction, wheat spiked at the start of extraction, maize spiked at the end of extraction and wheat spiked at the end of extraction.
Sample analysis
Microtitre plates were spotted as described in section 3.7. Antibodies for ZEA (ABZ 1/10,000), T2 (ABT-1 1/4000) and FUM (ABF-2 1/4000) were examined during the assay. Maize and wheat samples (n=8) were extracted following the sample preparation method described in 
Results and Discussion
Optimisation
In the optimisation of the ZEA assay it was noted that spot intensity was very low for the spotting concentration of 0.5 µg/ml with many spots not visible. Very little difference was observed in intensity between the four different spotting volumes (330, 670, 1000, 2000 pl) within each spotting concentration (0.5, 5 and 50 µg/ml). Nonetheless a spotting volume of 1000 pl was selected as visually spots were easier to see for the alignment of grids.
Additionally, intensity decreased as the alkaline phosphatase anti-rabbit IgG dilution increased to 1/20,000 with a dilution of 1/500 chosen for the assay. A spotting concentration for ZEA of a suitable intensity and differential between negative and positive for the development of a calibration curve. For the optimisation of T2 and FUM parameters it was observed that spots were not visible for FUM antibody ABF-1 and T2 antibodies ABT-1 and ABT-2 at the spotting concentration of 10 µg/ml. Very little difference in spot intensity was observed between 50, 100 and 200 µg/ml spotting concentrations for T2 and FUM. As the spotting concentration increased the sensitivity of the assay decreased and a higher antibody dilution was required.
However, at the highest antibody dilutions the spots were barely visible with quite low spot intensities obtained. A spotting concentration of 50 µg/ml was therefore selected for T2 and FUM with antibody dilutions 1/4000 for both ABT-1/ABT-2 and ABF-1/ABF-2 antibodies as these conditions provided suitable intensity and differential between negative and positive to allow further assay development.
Individual calibration curves
Individual calibration curves, in a nine spot format (3x3 array), for ZEA (ABZ antibody), T2 (ABT-1 and ABT-2 antibodies) and FUM (ABF-1 and ABF-2 antibodies) using both PBS and methanol were examined. For T2 and FUM antibodies ABT-1 and ABF-2 were selected for the final multiplex assay as illustrated in Figures 1 and 2 . The average spot intensity of the nine spots per well was calculated and the average of the two wells was determined. The spot intensity for ZEA was approximately 2000 pixels (0 ppb) and sensitivity of the assay (based on the 50 % inhibition concentrations) decreased from 21.9 ppb to 100.2 ppb between PBS and methanol calibration curves (Table 1 ). Since mycotoxins such as ZEA tend to be lipophilic and organic solvents are often used to extract analytes from samples for immunoassays it is necessary to use a water miscible organic solvent in the assay buffer for ELISAs. Methanol tends to be the most widely used. However, it has been shown that with increased methanol concentration the sensitivity of the assay can decrease [37] . The methanol may affect either the immobilised protein conjugate or the antibody protein structure causing reduced binding to the ZEA due to interference and thereby decreasing the sensitivity. For T2 the spot intensity for both antibodies was very low at approximately 800 -1000 pixels (0 ppb) whereby grids had to be manually aligned. Sensitivity for both the ABT-1 and ABT-2 antibodies were very similar based on the 50 % inhibition concentrations (1 ppb) and remained similar between PBS and methanol calibration curves ( Table 1 ). The ABT-1 antibody was selected for the multiplex calibration curve as the intensity was slightly higher and whereby automatic grid alignment could be achieved to determine signal intensity. For FUM the starting intensity (0 ppb) for the ABF-2 antibody was slightly higher at approximately 2000 pixels compared to the ABF-1 antibody (1500 pixels). Sensitivity for both the ABF-1 and ABF-2 antibodies were very similar based on the 50 % inhibition concentrations; however, sensitivity did decrease from approximately 60 ppb to 100 ppb between PBS and methanol calibration curves (Table 1) .
Again, the methanol may affect the FUM antibody and cause some interference in binding to FUM decreasing the sensitivity. The ABF-2 antibody was selected as the antibody to use for the multiplex calibration curve because the intensity was much higher. Reduced sensitivities for the methanol calibration curves was possibly because methanol will cause reduced antibody binding due to the target due to solvent effects on the antibody. However, for these mycotoxins due to their solubility properties it is necessary to use an extraction solvent in the sample preparation methods.
Multiplex calibration curves
Multiplex calibration curves, in a 12 spot format (4x3 array), for ZEA (ABZ antibody), T2
(ABT-1 antibody) and FUM (ABF-2 antibody) using both PBS (Figure 1 days. Improved curve shapes were produced for T2 as multiplex calibration curves with only a slight difference between PBS and methanol. Spot intensity for T2 was very low therefore the grid alignment had to be completed manually. Calibration curves for FUM were similar between PBS and methanol until the final two standards. It is, however, more difficult to align the grids when the spot intensity is faint and so this may account for this difference. Sensitivity, assessed by examining the 50 % inhibition concentration of the assay, for the nanoarray for ZEA, T2 and FUM are presented in Table 1 . Sensitivity decreased for ZEA in PBS from 21.9 ppb (individual) to 70.1 ppb (multiplex) and similarly for methanol from 100.2 ppb (individual) to 172.4 ppb (multiplex). The standard deviation of the intensity of each spot is greater in the multiplex assay for ZEA indicating that there may be interference occurring from the other assays. Sensitivity decreased for T2 in PBS from 1.0 ppb (individual) to 2.8 ppb (multiplex) and similarly for methanol from 0.9 ppb (individual) to 3.2 ppb (multiplex). Similar to ZEA the standard deviation of the intensity of each spot is greater in the multiplex assay for T2
indicating that there may be interference occurring from the other assays. Finally, sensitivity also decreased for FUM in PBS from 63.9 ppb (individual) to 90.9 ppb (multiplex) and similarly for methanol from 105.0 ppb (individual) to 129.3 ppb (multiplex). Reduced sensitivities between the individual and multiplex calibration curves is possibly due to interference and non-specific binding of reagents between the assays. As the standard deviation of the spots increased more significantly in the ZEA and T2 assays when multiplexed compared to the FUM assay the reagents in these assays may be interacting. Multiplexing assays with different antibodies may lead to some degree of interference between antibodies and between targets even due to steric hindrance. Nonetheless, certain benefits of multiplexing outweigh the loss of sensitivity in most applications.
Cross reactivity
For the multiplex nanoarray the characterisation of the antibodies, especially in regard to their cross reactivity is important to know. The cross reactivity profile for each antibody was examined by analysing individual calibration curves prepared in methanol for ZEA, T2, HT2, FUM B1, FUM B2, FUM B3 and DON as illustrated in Figure 3 . The results demonstrated that the T2 antibody ABT-1 showed 74 % cross reactivity to HT2. FUM antibody ABF-2 showed 48 % and 24 % cross reactivity to FUM B2 and FUM B3 respectively. Moreover, the antibodies used turned out to be specific for their corresponding mycotoxin and showed minimal to no cross reactivity for the concentrations used in the assay for the other mycotoxins (Figure 3 ).
Intra and inter spotting precision
The data for the spotting precision of each mycotoxin was examined by analysing a 0 pbb standard in all 96 wells of a three-plex (ZEA, T2 and FUM) spotted system using both PBS and methanol. Results are shown in Table 2 . Intra-spotting precision was 6, 11 and 10 % for PBS and 5, 11 and 12 % for methanol for ZEA, T2 and FUM respectively. Inter-spotting precision was 4, 14 and 6 % for PBS and 3, 9 and 16 % for methanol for ZEA, T2 and FUM respectively over 3 spotting days.
Sample preparation
Both maize and wheat were extracted according to the protocol described in section 3.11. All extracts were diluted 1 in 3 and 1 in 15 to give a final dilution of 15 and 75 and a percentage of methanol at 23.3 %. Sample 9E was highly contaminated for T2 and FUM and therefore the extract was diluted 1 in 60 to give a final dilution of 300 so that the response would present within the calibration range. Taking into account the 50 % inhibition concentration and the 1 in 3 extraction dilution this converts to 1050.9, 42.0 and 1364.1 µg/kg for ZEA, T2 and FUM respectively which meets the regulatory limits for these mycotoxins in feed. It was observed that for wheat samples using only a 1 in 3 dilution produced a white cloudy extract. There is some component of the wheat that is causing a cloudy supernatant which is not present in the maize. It may therefore be better to increase the dilution to 1 in 15 for the assay (final dilution 75). This would dilute out the extract and minimize the cloudy extract interfering with the test.
Matrix effects
The calibration curves were assessed for ZEA (ABZ antibody), T2 (ABT-1 antibody) and FUM (ABF-2 antibody) for matrix effects in maize ( Figure 4 ) and wheat ( Figure 5 ). . For ZEA the intensity for the 0 ppb standard for maize and wheat were very similar to the PBS and methanol curves. However, the difference in the curve shape was more pronounced for the maize and wheat. Sensitivity for ZEA in matrix is somewhat reduced for both maize and wheat (Table 1) .
For T2 the intensity for the 0 ppb standard for maize and wheat was approximately 16 % and 13 % lower than the PBS and methanol curves respectively. The calibration curves for maize showed a large drop between the first two standards giving a poor curve shape. In comparison, the wheat produced a better curve shape and compared better with the PBS and methanol curves. Sensitivity for T2 for both maize and wheat is reduced when spiked at the start of the extraction, however, is similar to PBS and methanol curves when spiked at the end into negative extract (Table 1) . For FUM the intensity for the 0 ppb standard for maize was approximately 11 % lower than the PBS and methanol curves with wheat showing an intensity approximately 7 % higher in comparison. The calibration curve for the maize spiked at the end of the extraction showed a slightly different curve shape compared to the others. Sensitivity for FUM in matrix is somewhat reduced for both maize and wheat (Table 1) . A differential in the calibration curves prepared pre and post extraction illustrates the extent of the recovery of the assay. It was evident that due to substantial differences between these two curves that recovery was not 100% and whereby some mycotoxins may not be extracted during the extraction process. This would mean that the concentration of unknown samples should be determined from a calibration curve prepared pre-extraction during the final validation of the assay or the extraction procedure should be examined further to help improve the recovery of the assay.
Sample analysis
The analysis of the wheat and maize samples (n=8) using the multiplex nanoarray in comparison with other screening methods and HPLC are presented in Table 3 . Comparing the nanoarray results to concentrations for ELISA, LFD and HPLC/MS it was observed that for ZEA there were five samples that correlate in terms of negative and positive results. Samples L2 and GT were both expected to be < 50 ppb but have a higher concentration when analysed by the mycotoxin nanoarray at 132 ppb and 206 ppb respectively. Additionally, sample MA110 had a higher concentration when analysed by the mycotoxin nanoarray. For the ZEA assay only ZEA was determined whereby for future work other analogues of ZEA should be examined to ensure differences between the assays are not due to the cross-reactivity towards these analogues. For T2 there were six samples that correlate in terms of negative and positive results.
Sample GT was expected to be < 5 ppb but had a higher concentration of 86 ppb when analysed by the mycotoxin nanoarray. Additionally, sample MA110 had a higher concentration when analysed by the mycotoxin nanoarray. Finally, for FUM there were seven samples that match up in terms of negative and positive results. The reference material MA110 had a higher concentration of 116 ppb when analysed by the mycotoxin nanoarray compared to the certified concentration of < 50 ppb. Differences detected for certain samples may be due to the non-homogeneity of the sample as it is well known that mycotoxins are very heterogeneous in nature [38] , sensitivities of the different testing platforms and possible variations in cross reactivity profiles of the antibodies used to analogues of the compounds in the screening tests as analysed in different laboratories at different times. The sample for analysis provided for the nanoarray study was relatively small and in this study the analysis by the different methods was performed over different sites and whereby the sample may have been stored under different conditions. The differences detected for certain samples may also be due to the heterogeneity in distribution of the mycotoxin in the sample provided to the different sites. It is well established that mycotoxin distribution in a sample can be very heterogeneous in nature and storage conditions are important. This paper is a proof of concept and feasibility study to show that the mycotoxin nanoarray application is highly feasible. Further work would include a single laboratory validation and substantive survey of real samples in direct analytical comparison with other routine testing platforms.
Image and Data Analysis
For the implementation of the nanoarray application the reader must be employed that can record the spot intensity at the spatially defined zones compared to the whole well as in current laboratory ELISA applications. For novice end users a current major drawback of the reader technology is the time required for image analysis and data processing. Currently all 96 wells are imaged and each image must be opened by the software for grid alignment and calculation of spot intensity. Aligning grids for one microtitre plate takes approximately 2 hr, generating 96 excel sheets. Further data processing can take a further 1 hr therefore data processing per plate can take up to 3 hr. This is not applicable from a commercial point and unless data processing software solutions can be addressed it would be unsuitable for commercial and routine laboratory use. Reference spots should be assessed and included in future work which may help with grid alignment. For this to be a viable method the reader software needs to be enhanced for automated data processing for all 96 wells generating calibration curves and interpolating unknown samples to these curves. Additionally, another drawback is that any dust or particles present in the well can interfere with the image and spot intensity especially if it is covering a spot within the nanoarray. Therefore, clean room facilities for production and use may need to be a consideration.
Conclusions
Monitoring programmes for mycotoxins have become a necessity because of the potential consequences to human and animal health. New innovations in technology applications to improve surveillance for the industry are essential. A sensitive and novel multiplex nanoarray has been developed allowing for the semi-quantitative and simultaneous screening of three regulated mycotoxins. The immunological format offers a high throughput detection method for ZEA, T2 and FUM, whereby with improved software utilities on the reader results, results would be available in around 70 min. The benefit to this system is that it follows established ELISA protocols whereby laboratories with immunological screening methods already in place have end users familiar to the steps in analysis and comparable to LFD offers a higher throughput of samples. The simplicity, sensitivity and comparative labour to ELISA of the mycotoxin nanoarray assay means it could be used as a screening method in a monitoring environment for the presence of these harmful mycotoxins in food. This technology demonstrates the potential feasibility for an easy to use and sensitive multiplex mycotoxin detection method. This study has shown some very promising data and required considerations that are worthy of further research to determine the nanoarray suitability for a commercial diagnostic test. Prior to implementation a full validation and inter-laboratory trial of the nanoarray should be conducted following accreditation guidelines for screening methods. 
